Eight-year prescription trends of memantine and cholinesterase inhibitors among persons 65 years and older in Germany

International Clinical Psychopharmacology

Volumn 25, Issue 1, 2010, Pages 29-36

  Hoffmann, Falk ^a   Van Den Bussche, Hendrik ^b   Glaeske, Gerd ^a   Kaduszkiewicz, Hanna ^b  

^a UNIVERSITY OF BREMEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cholinesterase inhibitors; Dementia; Germany; Health services research; Memantine

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ADULT; AGE; AGED; ARTICLE; CLINICAL PRACTICE; DEMENTIA; DRUG USE; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NORMAL HUMAN; PRESCRIPTION; PRIORITY JOURNAL; TREND STUDY;

AGE FACTORS; AGED; AGED, 80 AND OVER; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; DRUG UTILIZATION; FEMALE; GERMANY; HUMANS; MALE; MEMANTINE; PHYSICIAN'S PRACTICE PATTERNS; SEX FACTORS;

EID: 73449108377     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3283339496     Document Type: Article

References (21)

1. Andersen E, Silvius J, Slaughter S, Dalziel W, Drummond N (2008). Lay and professional expectations of cholinesterase inhibitor treatment in the early stage of Alzheimer's disease. Dementia 7:545-558.
2. Bickel H (2001). Demenzen im höheren Lebensalter: Schätzungen des Vorkommens und der Versorgungskosten. Z Gerontol Geriatr 34:108-115.
3. Bond J, Stave C, Sganga A, O'Connell B, Stanley RL (2005). Inequalities in dementia care across Europe: key findings of the Facing Dementia Survey. Int J Clin Pract 59 (Suppl 146):8-14. (Pubitemid 40333120)
4. Bramesfeld A, Grobe T, Schwartz F (2007). Who is diagnosed as suffering from depression in the German statutory health-care system? An analysis of health insurance data. Eur J Epidemiol 22:397-403.
5. Breslow NE, Day NE (1987). Statistical methods in cancer research, Vol.2, the design and analysis of cohort studies. Lyon: IARC Scientific Publications. No.82.
6. Federal Statistical Office (2006). Statistical Yearbook 2006. For the Federal Republic of Germany. Wiesbaden: Federal Statistical Office.
7. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al.; Alzheimer's Disease International (2005). Global prevalence of dementia: a Delphi Consensus Study. Lancet 366:2112-2117.
8. IQWiG (2007). Cholinesterase inhibitors in Alzheimer's disease. Final report A05-19A. Cologne: Institute for Quality and Efficiency in Health Care (IQWiG).
9. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H (2005). Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 331:321-327.
10. Kaduszkiewicz H, van den Bussche H, Zimmermann T (2008a). The evidence is not convincing. Int Psychogeriatr 20:260-279.
11. Kaduszkiewicz H, Bachmann C, van den Bussche H (2008b). Telling 'the truth' in dementia-do attitude and approach of general practitioners and specialists differ? Patient Educ Couns 70:220-226.
12. Maeck L, Haak S, Knoblauch A, Stoppe G (2007). Early diagnosis of dementia in primary care: a representative eight-year follow-up study in Lower Saxony, Germany. Int J Geriatr Psychiatry 22:23-31.
13. Maeck L, Haak S, Knoblauch A, Stoppe G (2008). Primary care physicians' attitudes related to cognition enhancers in early dementia: a representative eight-year follow-up study in lower saxony, Germany. Int J Geriatr Psychiatry 23:415-421.
14. National Institute for Health and Clinical Excellence (NICE) (2007). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease (amended). London (UK): National Institute for Health and Clinical Excellence (NICE). Technology appraisal guidance; no.111.
15. Oude Voshaar RC, Burns A, Olde Rikkert MG, European Dementia Consensus Network Group (EDCON) (2006). Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. Int J Geriatr Psychiatry 21:29-31.
16. Pariente A, Helmer C, Merliere Y, Moore N, Fourrier-Réglat A, Dartigues JF (2008). Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiol Drug Saf 17:655-660.
17. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. (2008). Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 148:379-397.
18. Schnee M (2008). Sozioökonomische Strukturen und Morbidität in den gesetzlichen Krankenkassen. In: Böcken J, Braun B, Amhof R, editors. Gesundheitsmonitor 2008. Gütersloh: Bertelsmann, pp. 88-104.
19. Schwabe U, Paffrath D (2001). Arzneiverordnungs-Report 2001. Heidelberg: Springer.
20. Schwabe U, Paffrath D (2008). Arzneiverordnungs-Report 2008. Heidelberg: Springer.
21. Wilkinson D, Sganga A, Stave C, O'Connell B (2005). Implications of the Facing Dementia Survey for health care professionals across Europe. Int J Clin Pract 59 (Suppl 146):27-31. (Pubitemid 40333122)